XML 45 R36.htm IDEA: XBRL DOCUMENT
v3.25.2

Financial Instruments and Fair Value Measurements (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2025
Fair Value Disclosures [Abstract] |
Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis | The following table presents the Company’s fair value hierarchy for those assets and liabilities measured at fair value on a recurring basis (in thousands):
|  | June 30, 2025 |  |  | December 31, 2024 |
|  | Level 1 |  |  | Level 2 |  |  | Level 3 |  |  | Level 1 |  |  | Level 2 |  |  | Level 3 |
Assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Marketable equity securities |  | $ | 10,908 |  |  | $ | — |  |  | $ | — |  |  | $ | 14,771 |  |  | $ | — |  |  | $ | — |
Derivative financial instruments |  |  | — |  |  |  | 12,605 |  |  |  | — |  |  |  | — |  |  |  | 31,145 |  |  |  | — |
Liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Derivative financial instruments |  |  | — |  |  |  | (2,836 | ) |  |  | — |  |  |  | — |  |  |  | (1,598 | ) |  |  | — |
Schedule realized and unrealized gain (loss) on marketable securities | The following table represents the realized and unrealized gains (losses) on marketable securities included in Realized and unrealized holding gains (losses) on investments and other on the Company’s Condensed Consolidated Statements of Operations (in thousands):
| Three Months Ended June 30, |  |  | Six Months Ended June 30, |
| 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
Realized gain on marketable securities, net | $ | 5,406 |  |  | $ | 3,586 |  |  | $ | 5,406 |  |  | $ | 7,580 |
Less: previously recognized unrealized gains on marketable securities sold during the period |  | (5,406 | ) |  |  | (3,586 | ) |  |  | (5,406 | ) |  |  | (7,580 | )
Unrealized (losses) gains on marketable securities still held as of the end of the period and through the disposition date on marketable securities sold during the period |  | (225 | ) |  |  | (2,020 | ) |  |  | 1,543 |  |  |  | (4,035 | )
Realized and unrealized (losses) gains on marketable securities, net | $ | (225 | ) |  | $ | (2,020 | ) |  | $ | 1,543 |  |  | $ | (4,035 | )
Schedule of Items Measured at Fair Value on Nonrecurring Basis | Impairment charges for the six months ended June 30, 2025 are as follows (in thousands):
|  |  |  |  |  |  |  | Impairment Charge (a) |
Property Location |  | Owner |  | Triggering Event |  | Effective Date |  | Total |  |  | Acadia's Share |
New York, NY |  | Fund III |  | Reduced holding period |  | June 30, 2025 |  | $ | 7,240 |  |  | $ | 1,777 |
New York, NY |  | Fund IV |  | Reduced holding period |  | June 30, 2025 |  |  | 17,400 |  |  |  | 3,991 |
Total 2025 Impairment Charges (b) |  |  |  |  |  |  |  | $ | 24,640 |  |  | $ | 5,768 |
(a) The fair value of the Fund III property, which was classified as held for sale, was based on the purchase and sale agreement, excluding selling costs. The fair value of the Fund IV property was estimated using a discounted cash flow model with a discount rate of 9.25% and a capitalization rate of 8.25%, resulting in a Level 3 fair value of $28.6 million as of the June 30, 2025 measurement date. (b) An additional $0.4 million impairment related to the Company’s investment in Fifth Wall (Note 4) is included in Realized and unrealized holding gains (losses) on investments and other, in the Company’s Condensed Consolidated Statement of Operations.
Schedule of Derivative Financial Instruments | The Company had the following interest rate swaps and caps for the periods presented (information is as of June 30, 2025, unless otherwise noted, and dollars in thousands):
|  |  |  |  |  |  |  |  | Strike Rate |  |  |  | Fair Value |
Derivative Instrument |  | Aggregate Notional Amount |  |  | Effective Date |  | Maturity Date |  | Low |  |  | High |  | Balance Sheet Location |  | June 30, 2025 |  |  | December 31, 2024 |
Core |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Interest Rate Swaps |  | $ | 581,000 |  |  | May 2022—Apr 2025 |  | Apr 2026—Jul 2030 |  | 1.98% | — |  | 3.35% |  | Other Assets |  | $ | 12,237 |  |  | $ | 28,173 |
Interest Rate Swaps |  |  | 252,000 |  |  | Dec 2022—Jun 2025 |  | Nov 2026—Apr 2030 |  | 3.41% | — |  | 4.50% |  | Accounts payable and other liabilities |  |  | (1,997 | ) |  |  | (1,316 | )
|  | $ | 833,000 |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | 10,240 |  |  | $ | 26,857 |
Fund II |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Interest Rate Swap |  | $ | 50,000 |  |  | Jan 2023 |  | Dec 2029 |  | 3.23% | — |  | 3.23% |  | Other Assets |  | $ | 273 |  |  | $ | 1,615 |
Fund III |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Interest Rate Cap |  | $ | 33,000 |  |  | Sep 2023 |  | Oct 2025 |  | 5.50% |  | — |  | 5.50% |  | Other Assets |  | $ | — |  |  | $ | 1 |
Fund IV |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Interest Rate Cap |  | $ | 54,500 |  |  | Dec 2023 |  | Dec 2025 |  | 6.00% |  | — |  | 6.00% |  | Other Assets |  | $ | — |  |  | $ | 2 |
Fund V |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Interest Rate Swaps |  | $ | 65,885 |  |  | Jan 2023—May 2023 |  | May 2026—Dec 2027 |  | 3.36% | — |  | 3.47% |  | Other Assets |  | $ | 95 |  |  | $ | 1,352 |
Interest Rate Swaps |  |  | 151,466 |  |  | Mar 2024—Jun 2025 |  | Mar 2026—Feb 2028 |  | 3.43% | — |  | 4.49% |  | Accounts payable and other liabilities |  |  | (839 | ) |  |  | (282 | )
Interest Rate Cap |  |  | 32,200 |  |  | Aug 2023 |  | Sep 2025 |  | 5.00% | — |  | 5.00% |  | Other Assets |  |  | — |  |  |  | 2 |
|  | $ | 249,551 |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | (744 | ) |  | $ | 1,072 |
Total asset derivatives |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | 12,605 |  |  | $ | 31,145 |
Total liability derivatives |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | (2,836 | ) |  | $ | (1,598 | )
Schedule of Other Financial Instruments Carrying Values and Fair values | The Company’s other financial instruments had the following carrying values and fair values as of the dates shown (dollars in thousands, inclusive of amounts attributable to noncontrolling interests where applicable):
|  |  |  |  | June 30, 2025 |  |  | December 31, 2024 |
|  | Level |  |  | Carrying Amount |  |  | Estimated Fair Value |  |  | Carrying Amount |  |  | Estimated Fair Value |
Notes Receivable (a) |  |  | 3 |  |  | $ | 154,682 |  |  | $ | 156,695 |  |  | $ | 126,584 |  |  | $ | 127,485 |
City Point Loan (a) |  |  | 3 |  |  |  | 66,741 |  |  |  | 67,722 |  |  |  | 66,741 |  |  |  | 68,204 |
Mortgage and Other Notes Payable (a) |  |  | 3 |  |  |  | 1,010,972 |  |  |  | 1,005,986 |  |  |  | 958,947 |  |  |  | 954,276 |
Investment in non-traded equity securities (b) |  |  | 3 |  |  |  | 3,512 |  |  |  | 3,512 |  |  |  | 4,073 |  |  |  | 4,073 |
Unsecured notes payable and Unsecured line of credit (c) |  |  | 2 |  |  |  | 803,500 |  |  |  | 807,503 |  |  |  | 589,000 |  |  |  | 589,018 |
(a) The Company estimates the fair value of financial instruments using a discounted cash flow model. This model incorporates assumptions such as current market rates and, where applicable, the credit quality of the borrower or tenant. In addition, the Company evaluates the value of the underlying collateral, considering factors such as collateral quality, borrower creditworthiness, time to maturity, and prevailing market conditions. These fair value estimates exclude unamortized discounts and deferred loan costs. As of the reporting date, the estimated market interest rates used in the valuation ranged from 3.93% to 13.11% for the Company’s notes receivable and City Point Loan, and from 5.27% to 7.70% for the Company’s property mortgage loans and other notes payable, depending on the specific characteristics of each loan. (b) Includes the Operating Partnership’s cost-method investment in Fifth Wall (Note 4). (c) The Company estimates the fair value of its unsecured notes payable and unsecured line of credit using quoted market prices in active or brokered markets, when available. In instances where observable market prices are not available due to limited or no trading activity, the Company estimates fair value using a discounted cash flow model. This model incorporates a rate that reflects the average yield of comparable instruments issued by market participants with similar credit risk profiles.

X
- Definition Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details
Name: | us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11 + Details
Name: | us-gaap_FairValueByBalanceSheetGroupingTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_FairValueDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of realized and unrealized gain (loss) on investment in security. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details
Name: | us-gaap_GainLossOnInvestmentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4B -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B + Details
Name: | us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration